A²I™

Evidence gap analysis and funding intelligence

A²I™ maps the evidence generated — or planned — against historical MSAC, NICE, PHARMAC, and CMS reimbursement decisions. It identifies exactly where the current evidence falls short and what needs to change: which gaps will cause a reimbursement rejection, and — working jointly with Aesculytics — what evidence is needed to close each one, whether that’s in silico modelling or another form of evidence generation.

Pre-protocol intelligence

Evidence gaps are mapped against your planned evidence strategy before a protocol is locked — so you can redesign it to satisfy the funder and the regulator at the same time, not one after the other.

Reimbursement alignment

Planned evidence is analysed against published decision standards and historical committee outcomes across MSAC, NICE, PHARMAC, and CMS — surfacing the specific gaps that consistently drive negative recommendations.

Built with Aesculytics

A²I™ and Aesculytics work out together whether in silico modelling can close a gap. If it can, we say so. If it can't, we map out what kind of evidence you actually need to generate instead — based on what's worked in similar real decisions, not a guess.

Evidence-to-Precedent Match

We check every claim in your planned evidence strategy against real MSAC, NICE, PHARMAC, and CMS decisions — named rejection and approval patterns, not general commentary.

Claim Weight Score

We score how much your funding case depends on each part of your evidence plan, and how well-evidenced it is right now — so you know which claims are load-bearing before you commit to a protocol.

Evidence Certainty Rating

Each piece of supporting evidence is graded against the standards funders actually use — market by market, so weak spots don't hide behind one blended number.

Funding Readiness Report

One score per target market, plus a ranked list of what's costing you points and what closes each gap — the document you take into a submission decision, not a dashboard you have to interpret yourself.

Regulatory clearance is not funding. Passing the regulator and getting funded are two different tests. We score the funding test — the one that decides whether patients actually get your device — before your protocol is locked and while you can still change your evidence plan.